The immune system is an important means to control cancer. It is also the source of hematologic malignancies. The goals of the Immunology/Immunotherapy (IMM) Program are to support basic, translational, and clinical research to improve the immune response to cancer, and to translate understanding of hematopoietic cell development into treatment of hematologic malignancies. These goals are encompassed in 3 Specific Aims: 1. to develop and optimize the efficacy of antigen-specific immunotherapeutics; 2. to understand and modulate T cell function and regulation in the tumor microenvironment; 3. to understand normal pathways of hematopoietic cell development and their dysregulation in human hematologic malignancies.
Each aim i ncludes outstanding basic science investigations, and highly collaborative translational initiatives and clinical trials. The Program co-leaders are internationally recognized for their work in tumor antigen identification, induction of tumor-specific CD8 T cell responses, and cancer immunotherapy clinical trials. The Program consists of 30 members and 7 associate members from 9 departments/divisions in the School of Medicine. Total extramural funding is over $11.17M, including over $4.04M from the NCI and over $4.77M from other NIH institutes. Program members have published 216 papers over the last 5 years, of which 12% were inter-programmatic and 16% were intraprogrammatic. The Program supports research in progress presentations and seminars to engender new directions and collaborations; pilot funding to encourage development of promising collaborations and ideas; and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen clinical trials led by Program members are open to enrollment across 5 cancer histologies (pancreatic cancer, breast cancer, head and neck cancer, prostate cancer, and melanoma). They include 10 investigator-initiated trials, of which three are multicenter. These trials are evaluating cancer vaccines, checkpoint blockade antibodies and combination immunotherapies. These trials test hypotheses arising from laboratory science and also bring tissue to the laboratories to investigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for continued advances in understanding of the immune system and utilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Virginia
United States
Zip Code
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8

Showing the most recent 10 out of 539 publications